Global Advanced Research Journal of Medicine and Medical Sciences (GARJMMS) ISSN: 2315-5159
December 2017 Special Issue Vol. 6(12), pp. 341-351
Copyright © 2017 Global Advanced Research Journals

Full Length Research Paper

Revisiting the phenomenon of concomitant tumor resistance and its impact on established metastases of murine and human origin

Ariel Strazza¹ Daniela R. Montagna¹, Mónica Aixala², Roberto P. Meiss³, Paula Chiarella¹ and Raúl A. Ruggiero¹

¹Department of Experimental Oncology, IMEX-CONICET, Academia Nacional de Medicina de Buenos Aires, Argentina.
²Central Laboratory of ClinicalAnalysis, Academia Nacional de Medicina de Buenos Aires, Argentina.
³Department of Pathology, Instituto de Estudios Oncológicos,Academia Nacional de Medicina de Buenos Aires, Argentina.

*Corresponding Author E-mail: ruloruggiero@yahoo.com.ar; Telephone: 54-11-4805-3411 

Accepted 8 December, 2017

Abstract

Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host inhibits the growth of secondary tumor implants. The relevance of CR to mechanisms of metastases control has been highlighted by numerous observations showing that the removal of human and murine tumors may be followed by an abrupt increase in metastatic growth. This body of evidence suggests that, upon certain circumstances, a primary tumor would exert a controlling action on its metastases that can be considered as natural secondary tumor implants spontaneously developed during the primary tumor growth. In this article we revised both former and recent evidence accounting for this fact in both experimental and clinical settings and discussed the situations in which tumor removal would be or would not be recommended. In addition, we analyzed the different mechanisms historically proposed to explain CR especially focusing on the last investigations of our laboratory concerning the importance of tyrosine isomers as mediators of the phenomenon of CR and on their capacity to inhibit established metastases of both murine and human origin. Our investigations aimed to elucidate the molecular basis of the phenomenon of CR might stimulate the design of new strategies aimed to limit the development of metastases, an issue of critical importance for patients afflicted by malignant diseases.

Keywords: Metastases, concomitant tumor resistance, murine and human tumors, tyrosine isomers.

References

Ando K, Hunter N, Peters L (1979). Immunologically nonspecific enhancement of artificial lung metastases in tumor-bearing mice. CancerImmunol. Immunother. 6: 151-156.

Bashford E, Murray J, Haaland M (1908). General results of propagation of malignant new growths. In: E Bashford (ed. London:Taylor and Francis), Third scientific report on the investigation of the Imperial Cancer Research Fund. 3: 262-268.

Bertin C, Weston LA, Huang T, Jander G, Owens T, Meinwald J, Schroeder FC (2007). Grass roots chemistry: meta-tyrosine, an herbicidal nonproteinaminoacid. PNAS. 104:16964-16969.

Bonfil RD, Ruggiero RA, Bustuoabad OD, Meiss RP, Pasqualini CD (1988). Role of concomitant resistance in the development of murine lung metastases. Int. J. Can. 41: 415-422.

Brunschwig A, Southam CM, Levin A (1965). Host resistance to cancer. Clinical experiments by homotransplants, autotransplants and admixture of autologous leucocytes. Ann. Surg. 162: 416-425.

Bruzzo J, Chiarella P, Meiss RP, Ruggiero RA (2010).  Biphasic effect of a primary tumor on the growth of secondary tumor implants, J. Can. Res. Clin. Oncol. 136: 1605–1615.

Chen J, Sprouffske K, Huang Q, Maley CC (2011). Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PLoS One. 6(4): e17933.

Chiarella P, Bruzzo J, Meiss RP, Ruggiero RA (2012). Concomitant tumor resistance Cancer Lett. 324: 133-41, 2012. 

Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP (2003). Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 4:760-768.

Demicheli R, Retsky MW, Hrushesky WJM, Baum M, Gukas ID (2008). The effects of surgery on tumor growth: a century of investigations Annals of Oncology 19: 1821-1828.

Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky JM, Retsky MW, Valagussa P, Bonadonna G (2005). Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol16: 1449-1457.

DeWys WD (1972). Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Can. Res. 32:374-379.

Di Gianni PD, Franco M, Meiss RP, Vanzulli S, Piazzon I, Pasqualini CD, Bustuoabad OD, Ruggiero RA (1999). Inhibition of metastases by a serum factor associated to concomitant resistance induced by unrelated murine tumors. Oncol. Rep. 6: 1073-1084.

Ehrlich P (1906). Experimentelle Carcinomstudienanmausen. In: P.Ehrlich (ed. Jena, Germany: Gustav Fischer), Arbeitenausdem KoiglichenInstitut fur Experimentelle Therapiezu Frankfurt/ AM. pp. 77-103.

Elkabets M, Gifford AM,  Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS (2011). Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblast in mice. J. Clin. Invest. 12: 784–799.

Franco M, Bustuoabad OD, di Gianni PD, Goldman A, Pasqualini CD, Ruggiero RA (1996). A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic tumours. Br J Cancer74: 178-186.

Franco M, Bustuoabad OD, di Gianni PD, Meiss RP, Vanzulli S, Buggiano V, Pasqualini CD, Ruggiero RA (2000). Two different types of concomitant resistance induced by murine tumors: Morphological aspects and intrinsic mechanisms. Oncol. Rep. 7: 1053-1063.

Gershon RK, Carter RL, Kondo K (1967). On concomitant immunity in tumor-bearing hamsters. Nature (London). 213: 674-676.

Gorelik E (1983). Concomitant tumor immunity and the resistance to a second tumor challenge. Adv. Can. Res. 39: 71-120.

Gorelik E (1982). Antimetastatic concomitant immunity. In: Tumor Invasion and Metastasis. (Eds. Liotta LA and Hart IR, The Hague. MartinusNijhoff Publishers); p.113-131.

Glick AB, Yuspa SH (2005).Tissue homeostasis and the control of the neoplastic phenotypein epithelial cancers. Semin. Can. Biol. 15: 75-83.

Guba M, Cernaianu G, Koehl G, Geissier EK, Jauch KW, Anthuber M, Falk W, Steinhauer M (2001). A primary tumor promotes dormancy of solitary tumor cells beforeinhibiting angiogenesis. Can. Res. 61: 5575-5579.

Gurer-Orhan H, Ercal N, Mare S, Pennathur S, Orhan H, Heinecke JW (2006). Misincorporation of free m-tyrosine into cellular proteins: a potential cytotoxic mechanism for oxidized amino acids. Biochem. J. 395: 277-284.

Gueron G, Anselmino N, Chiarella P, Ortiz EG, Lage Vickers S, Páez AV, Giudice J, Contin MD, Leonardi D, Jaworski F, Manzano V, Strazza A, Montagna DR, Cotignola J, D’Accorso N, Woloszynska-Read A, Navone N, Meiss RP, Ruggiero RA, Vázquez E (2017). Game-changing restraint of ROS-damaged phenylalanine upon tumor metastases prostate cáncer, Cell Death and Disease (in press).

Hoskins WJ (1989). The influence of cytoreductive surgery on progression –  free interval and survival in epithelial ovarian cancer, Baillieres Clin. Obstet. Gynecol. 3: 59–71.

Iversen P, Madsen PO, Corle DK (1995). Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: twenty three years follow-up of a prospective andomized study. Scan. J. Urol. Neph. 172: 65-72.

Janik P, Bertram J, Szaniawska B (1981). Modulation of lung tumor colony formation by a subcutaneously growing tumor, J. Natl. Can. Inst. 66: 1155–1158.

Jirtle RL, Michalopoulus G (1982). Effects of partial hepatectomy on transplanted hepatocytes. Can. Res. 42: 3000-3004.

Joseph B, Berishvili E, Benten D, Kumaran V, Liponava E, Bhargava K, Palestro C, Kakabadze Z, Gupta S (2004). Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions. Nat. Med. 10: 749-753.

Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T (2004). Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J. Bone Joint Surg. Br. 86; 143-147.

Keller R (1985). Repression of lymphatic metastasis by a second implant of the same tumor. Invasion Metastasis 5: 295-308.

Ketcham AS, Kinsey DL, Wexler H, Mantel N (1961). The development of spontaneous metastases after the removal of a “primary” tumor. Cancer. 14: 875-882.

Lange PH, Hekmat K, Bosl G, Kennedy BJ, Fraley EE (1980). Accelerated growth of testicular cancer after cytoreductive surgery. Cancer. 45: 1498-1506.

Lausch R, Rappe F (1969). Concomitant immunity in hamsters bearing DMBA-induced tumor transplants. Int. J. Can. 4: 226-231.

Lekanidi K, Vlachou PA, Morgan B, Vasanthan S (2007). Spontaneous regression of metastatic renal cell carcinoma: case report, J. Med. Case Reports 1: 89.

Ling J, Yadavalli SS, Ibba M (2007). Phenylalanyl-tRNA synthetase editing defects result in efficient mistranslation of phenylalanine codons as tyrosine. RNA. United States 13:1881–1886.

Lokick J (1997). Spontaneous regression of metastatic renal cancer. Case report and literaturereview, Am. J. Clin. Oncol. 20: 416–418.

Machuca D, Chiarella P, Montagna D, Dran G, Meiss RP, Ruggiero RA (2015). Meta-tyrosine: A powerful anti-metastatic factor with undetectable toxic-side effects. Medicina (Bs.As.) 75: 1-5.

Man N, Chen Y, Zheng F, Zhou W, Wen LP (2016). Induction of genuine autophagy by cationic lipids in mammalian cells. Autophagy. United States. 6:449–454.

McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA Reinhardt TAF, Harris LN, Hylander BL,  Repasky EA, Weinberg RA (2008). Systemic endocrine instigation of indolent tumor growth requires osteopontin, Cell. 133: 994–1005.

Meiss RP, Bonfil RD, Ruggiero RA, Pasqualini CD (1986). Histologic aspects of concomitant resistance induced by nonimmunogenic tumors. J. Natl. Can. Inst. 76: 1163-1175.

Mestier L,  Manceau G,  Neuzillet C, Bachet JP, Spano JP, Kiammanesh R, Vaillant JC, Bouche O, Hannoun L, Karoui M (2014). Primary tumor resection in colorectal cancer with unresectable, synchronous metastases: a review. World J. Gastro. intest. Oncol. 6: 156-169.

Nakahara W, Fukuoka F (1958). The newer concept of cancer toxin. Adv. Can. Res. 5: 157-177.

Nguyen DH, Truong PT (2011). A debate on locoregional treatment of the primary tumor in patients presenting with stage IV breast cancer. Expert Rev. Antican Ther. 11: 1913-1922.

O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, CaoY, Sage EH, Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79: 315-328.

Peeters CF, de Waal RM, Wobbes T, Ruers TJ (2008). Metastatic dormancy imposed by the primary tumor: does it exist in humans? Ann. Surg. Oncol. 15: 3308-3315.

Prehn RT (1991). The inhibition of tumor growth by tumor mass. Can. Res. 51: 2-4.

Prehn RT (1993). Two competing influences that may explain concomitant tumor resistance. Can. Res. 53: 3266-3269.

Ray A, Ghosh SK (2014). Long natural history of spontaneous regression: a rare outcome of metastatic renal cell carcinoma. Clin. Can. Invest. J. 3: 447-449.

Retsky, MW, Demicheli R, Hrushesky WJM, Baum M, Gukas ID (2008). Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS. 116: 730-741.

Ruggiero RA, Bustuoabad OD, Bonfil RD, MeissRP, Pasqualini CD (1985). “Concomitant immunity” in murine tumours of non-detectable immunogenicity. Br. J. Can. 51: 37-48.

Ruggiero RA, Bustuoabad OD, Cramer P, Bonfil RD, Pasqualini CD (1990). Correlation between seric antitumor activity and concomitant resistance in mice bearing non-immunogenic tumors. Can. Res. 50: 7159-65.

Ruggiero RA, Bustuoabad OD (2006). The biological sense of cancer: a hypothesis. Theor. Biol. Med. Mod. 3: 43.

Ruggiero RA, Bruzzo J, Chiarella P, di Gianni P, Isturiz MA, Linskens S, Speziale N, Meiss RP, Bustuoabad OD, Pasqualini CD (2011). Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Can. Res. 71: 7113-7124.

Ruggiero RA, Bruzzo J, Chiarella P, Bustuoabad OD, Meiss RP, Pasqualini CD (2012). Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Can. Res. 72 (2012): 1043-1050.

Ruggiero RA., Machuca D, Chiarella P, Gueron G, Vázquez E, Meiss RP, Dran G (2015). Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance and exhibit a powerful anti-metastatic effect with undetectable toxic-side effects. J. Can. Sci. Ther. 7: 8.

Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H, et al. (2016). Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity. Mol. Cell [Internet]. Elsevier 48:667–80. Available from: http://dx.doi.org/10.1016/j.molcel.2012.09.013

Slesser AAP, Khan F, Chau I, Khan AZ, Mudan S, Tekkis PP, Brown G, Rao S (2014). The effect of a primary tumor resection on the progression of synchronous CRLMs. EJSO 41: 484-492.

Southam CM (1964). Host defense mechanisms and human cancer. Ann. Inst. Pasteur. 107: 585-597.

Strazza A, Montagna D, Alcain J, Sequeira G, Vermeulen M, Ruggiero RA, Chiarella P (2017). Congress of Society of Biosciencies, Buenos Aires.

Sugarbaker EV, Thornthwaite J, Ketcham AS (1977). Inhibitory effect of a primary tumor on metastasis. In. SB Day, W Myers, P Stansly, S Garattini and M Lewis (eds), Cancer Invasion and Metastasis. Biological Mechanisms and Therapy, New York: Raven, p. 227-240.

Tadenuma K, Okonogi S (1924). Experimentelle Untersuchugen Metastasebei Mausecarcinom. Z Krebsforsch 21: 168-172.

Tohme S, Simmons RL, Tsung A (2017). Surgery for cancer: a trigger for metastases. Can. Res. 77: 1548-1552.

Tyzzer EE (1913). Factors in the production and growth of tumor metastases. J Med. Res. 28: 309-332.

Woglom WH (1929). Immunity to transplantable tumors. Cancer Rev. 4: 129-209.

Wyczolkowski M, Klima W, Bieda W, Walask K (2001). Spontaneous regression of hepatic metastases after nephrectomy and mastectomy of renal cell carcinoma, Urol. Int. 66: 119–120.